0001225208-24-003305.txt : 20240229 0001225208-24-003305.hdr.sgml : 20240229 20240229171221 ACCESSION NUMBER: 0001225208-24-003305 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ullem Scott B. CENTRAL INDEX KEY: 0001446989 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 24705047 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES CORPORATION STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0508 4 2024-02-29 0001099800 Edwards Lifesciences Corp EW 0001446989 Ullem Scott B. ONE EDWARDS WAY IRVINE CA 92614 1 CVP, Chief Financial Officer 1 Common Stock 2024-02-29 4 M 0 7255.0000 36.7500 A 26329.0000 D Common Stock 2024-02-29 4 S 0 7255.0000 85.5855 D 19074.0000 D Common Stock 266318.0000 I By Trust Employee Stock Option (Right to Acquire) 36.7500 2024-02-29 4 M 0 7255.0000 0.0000 D 2018-05-11 2024-05-10 Common Stock 7255.0000 14505.0000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. This transaction was executed in multiple trades at prices ranging from $85.02 to $86.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2024-02-29